Curated News
By: NewsRamp Editorial Staff
February 25, 2025

Soligenix CEO Provides Updates on HyBryte(TM) in Benzinga Interview

Reddit Discuss on RedditDiscuss on LinkedIn LinkedInDiscuss on Substack SubstackDiscuss on Telegram TelegramView History of this news story on GitHub Github
Source News Release

TLDR

  • Investors can benefit from Soligenix's promising phase 3 study of HyBryte, with preliminary results expected in mid 2026.
  • Soligenix, a late-stage biopharmaceutical company, is developing HyBryte for cutaneous T-cell lymphoma and synthetic hypericin for psoriasis.
  • Soligenix's focus on rare diseases like cutaneous T-cell lymphoma and psoriasis aims to improve treatment outcomes and quality of life.
  • Exciting updates from Soligenix's phase 3 study of HyBryte show promise for innovative treatments in the future.

Impact - Why it Matters

This news highlights the innovative work being done by Soligenix Inc. in the field of biopharmaceuticals, specifically in the development of treatments for rare diseases. The potential success of HyBryte(TM) could have a significant impact on patients suffering from cutaneous T-cell lymphoma and other inflammatory diseases.

Summary

Soligenix Inc.'s CEO, Christopher J. Schaber, discussed the company's focus on developing treatments for rare diseases like HyBryte(TM) in a recent interview with Benzinga's All-Access. The company is currently conducting a phase 3 study on HyBryte with preliminary results expected in mid-2026.

Source Statement

This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Soligenix CEO Provides Updates on HyBryte(TM) in Benzinga Interview

blockchain registration record for the source press release.